|
1. Biologie
|
|
|
|
1.1 Biologie - Gènes
|
|
|
Fusions in Solid Tumours [ESMO]
|
|
|
|
|
|
Identification
and targeting of oncogenic gene fusions called as one of the most
important breakthroughs in oncology over the past century.
|
|
|
|
|
|
|
4.7 Dép., diag. & prono. - Col de l'utérus
|
|
|
|
5. Traitements
|
|
|
Fine-tuning cancer medicine [MIT News]
|
|
|
|
|
|
While
other institutions have begun efforts in precision medicine as well,
the MIT Center for Precision Cancer Medicine stands out for using
engineering approaches to solve complex clinical challenges in cancer
treatment that are rooted in biology.
|
|
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
Biotech’s biggest unicorn is now worth $7.5 billion [STAT]
|
|
|
|
|
|
At
a closed-door investor event in September, the Cambridge, Mass.,
company said it had solved the scientific issues that made its earlier
mRNA treatments too toxic for clinical trials. The company has also
begun testing in humans an mRNA that would work in concert with approved
immunotherapies for cancer.
|
|
|
|
|
|
|
|
5.12.7 Immunothérapies - vaccins
|
|
|
|
Locally-Injected Immunotherapy Eradicates Tumors in Mice [The Scientist]
|
|
|
|
|
|
Scientists
at Stanford University injected a pair of molecules—an antibody against
a protein on the surface of T cells, known as OX40, and a short piece
of DNA called a CpG oligodeoxynucleotide—into various types of solid
tumors, including melanoma and breast and colon cancers, in mice.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
Tianjing Li: What’s not shared—building on the FDA’s transparency momentum [BMJ]
|
|
|
|
|
|
How
do clinical study reports (CSRs) released by FDA compare with those
released by EMA? Is voluntary submission sufficient to achieve the
transparency goal? I urge the scientific community to participate in the
FDA’s pilot programme and comment on the ease of access, as well as
usability and completeness of data in the released CSRs.
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
Record number of personalized medicines approved in 2017 [PhRMA]
|
|
|
|
|
|
Looking
ahead, more than 42 percent of medicines in development by
biopharmaceutical researchers have the potential to be personalized
medicines. In cancer, a remarkable 73 percent may be personalized
medicines, reflecting the major impact genetic and molecular science is
having on oncology research.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
As states target high drug prices, pharma targets state lawmakers [STAT]
|
|
|
|
|
|
With
federal officials seemingly unwilling or unable to come up with
legislation to control skyrocketing drug prices, that task is
increasingly moving to the states. But so is pharma muscle and money
opposing the measures, regulatory disclosures and corporate filings from
the last two years show.
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
World Cancer Day: Get the Facts [AACR]
|
|
|
|
|
|
The
World Cancer Day slogan, “We Can. I Can,” is a reminder that everyone,
whether in a collective group or as individuals, can play a part in
reducing the global burden of cancer.
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
6.9 Controverses
|
|
|
Richard Smith: Doctors and patients heading in opposite directions [BMJ Blogs]
|
|
|
|
|
|
One
fellow tweeter pointed out that specialisation is unavoidable because
of our increasing knowledge (I’d prefer the word information) about
people’s problems. My response was that machines are much better than
humans at remembering and finding knowledge. Doctors should concentrate
on the human parts of caring, if they can remember how.
|
|
|
|
|
|